Docetaxel and Cisplatin for Advanced Urothelial Cancer
Author Information
Author(s): del Muro X García, Marcuello E, Gumá J, Paz-Ares L, Climent M A, Carles J, Parra M Sánchez, Tisaire J L, Maroto P, Germá J R
Primary Institution: Institut Català d'Oncologia
Hypothesis
The study aims to evaluate the activity and toxicity of docetaxel plus cisplatin as first-line chemotherapy in patients with advanced urothelial cancer.
Conclusion
Docetaxel plus cisplatin is an effective and well-tolerated regimen for the treatment of advanced urothelial cancer.
Supporting Evidence
- Thirty-eight patients were treated with docetaxel and cisplatin.
- Overall response rate was 58%, with seven complete responses.
- The median overall survival was 10.4 months.
Takeaway
This study tested a new combination of medicines to help people with a type of cancer in their bladder and found it worked well for many patients.
Methodology
Patients received docetaxel and cisplatin every 21 days for up to six cycles, and their responses were evaluated using standard criteria.
Potential Biases
Potential biases may arise from the multicentre nature of the study and patient selection criteria.
Limitations
The study had a small sample size and was limited to specific patient demographics.
Participant Demographics
Patients were adults aged 18 and older with advanced urothelial cancer, including those with prior chemotherapy.
Statistical Information
Confidence Interval
95% CI, 41–74%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website